For clinical trials
Validate MRD endpoints. Move faster.
You build ctDNA endpoints into your European oncology trial with raw data access and co-publication built in.
For pharma teams and CROs running phase I to III oncology trials in Europe.
- Trial-arm cost reduction through earlier endpoint signal
- MRD endpoints validated in head-to-head studies
- EU regulatory readiness, GDPR-native logistics
- Protocol design support and co-publication
For Research & Labs
See signals others miss.
You detect parts-per-million variants in paediatric and early-stage samples your current platform calls negative.
For translational oncology groups.
-
Low-AF detection in low-input samples
-
Send samples, or run SiMSen-Seq on your own instruments
-
Full raw data access, open pipeline, client bioinformatics collaboration
-
Co-publication on translational findings
FOR CLINICS
Catch relapse before imaging does.
You see minimal residual disease in patients months ahead of standard surveillance, with EU logistics and time-zone-aligned support.
For premium private oncology clinics in the EU, EES, and the UK.
- Personalised ctDNA monitoring per patient
- Lead time over imaging-based surveillance
- EUR / SEK / GBP pricing, local logistics, time-zone working hours
- Interpretation support
Trusted by leading European clinics, hospitals and biotechs
